1335 / 1816
FDA approval pertuzumab
In 2013 the FDA granted accelerated approval to pertuzumab for use in
combination with docetaxel and trastuzumab for HER2+ patients.
NEOSPHERE: It nearly doubled the pCR rate
They concluded
“Large improvement in pCR rate was reasonable likely to predict clinical
benefit“
A confirmatory trial should be ongoing